(MedPage Today) — HOUSTON — Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor.
A pooled analysis of data from…
Source link : https://www.medpagetoday.com/meetingcoverage/soho/117333
Author :
Publish date : 2025-09-05 18:48:00
Copyright for syndicated content belongs to the linked Source.
